Clinical-stage biotechnology company developing AAV-based gene therapies, including one-time treatments for retinal and rare genetic diseases
Clinical-stage biotechnology company developing AAV-based gene therapies, including one-time treatments for retinal and rare genetic diseases. Its pipeline includes therapies for wet age-related macular degeneration, diabetic retinopathy, Duchenne muscular dystrophy, and MPS I and II.